Home>Services>Mouse DimAb Development

Sales Promotion Get free trial
Contact Us Phone:+86-18062749453 Email:info@dimabio.com
Please leave your suggestion or opinion, we will reply you as soon as possible, thank you!×

Mouse DimAb Development

Overview

Our team has decades of experience on high quality monoclonal antibody development services. DIMA’s DimAbTM development platform is a revolutionary technology platform for monoclonal antibody development. Different from hybridoma fusion platform, we can directly isolate IgG genes from B cells of immunized animals. At present, we have successfully completed a number of custom development projects with high satisfaction (Please see our customer testimonials).

Advantages

Mouse is the best animal model system to study human diseases. Before clinical trial, mouse disease model is commonly used to simulate the pathogenesis of human diseases and test the drug responses. Till today, more than 90% of the therapeutic antibody drugs were developed from mouse or humanized mouse. There are well-established systems to humanize mouse monoclonal antibodies. Therefore, mouse is still the first choice when coming for a therapeutic antibody drug developmental program.

Although mouse hybridoma technology was developed several decades ago, it is still the major working horse people commonly using for monoclonal antibody development. However, there are limitations in the preparation of monoclonal antibodies by traditional hybridoma methods, such as low fusion efficiency of hybridoma, long preparation process, unstable hybridoma cells, etc. DIMA’s DimAbTM technology platform for mouse monoclonal antibody development is a total revolution, which has a number of advantages.

Mouse DimAbTM Hybridoma mouse monoclonal antibody
Short development process (4-5 months) Long development process (8-10 months)
High project success rate(80-90%) Low project success rate(50%)
High cloning efficiency (thousands of clones from one immunized animal) Low cloning efficiency
Direct acquisition of antibody IgG gene sequence, easy to maintain and transmit information High cost of hybridoma cell preservation, Need separate cloning step to clone IgG gene
High quality consistency between batches, and possible to automate the process Hybridoma cells are unstable and might loss during passage
No need to kill animals (PBMCs are good enough) Animals need to be killed to separate the splenocytes

Application Scenario

Therapeutic antibody drug development Since the first mouse monoclonal antibody drug muromonab OKT3 was developed in 1986, now close to 100 monoclonal antibody drugs have been approved by FDA and it is a multi-hundred billion dollars market. Monoclonal antibodies have been used to treat different diseases, including cancer, infectious diseases, immunological disorders, etc. Many therapeutic antibody drugs become multi-billion dollar blockbuster, such as Humira (anti-tumor necrosis factor (TNF), Keytruda (anti-Pd-1), Praluent (anti-PCSK9), etc. In the future, the research and development trend of mouse monoclonal antibody will focus on new targets, new indications, new combinatorial treatment and so on.

The top 5 therapeutic antibody drugs in global sales by 2018 (Source: Genetic Engineering and Biotechnology News 2019-03-11)

Rank Drug name (trade name) Company Billion dollars
1 Humira AbbVie 19.9
2 Opdivo BMS 7.6
3 Keytruda Merck 7.2
4 Herceptin Roche 7.0
5 Avastin Roche 6.8

Major diseases treated by antibody drugs

Diseases Mechanism/target Representative drugs
Cancer blocking ligand binding cetuximab
CDC Effect Rituximab
ACDC Effect Trastuzumab
Block cell signal Pertuzumab
Inhibition of angiogenesis Bevacizumab
Immunosuppressant PD-1/L1 Monoclonal Antibody
Other Basiliximab, etc
Immunological Disorders Receptor blocking and regulation Omalizumab
Block cytokines Adalimumab
Depletion antigen producing cell Rituximab

Application in clinical diagnosis Since the approval of Herceptin and HER2 IHC detection reagents by FDA in 1998, mouse monoclonal antibodies have played an important role in clinical diagnosis. As of 2018, FDA has approved 35 companion diagnostic products and quite a number of immunological assaysuse mouse monoclonal antibodies. In addition, mouse monoclonal antibodies have also been widely used in the field of in vitro diagnosis.

Application in scientific research In the past 30 years, mouse monoclonal antibodies have played an important role in scientific research and are the basic reagents for a lot of immunological assays.

Comparisonsbetween rabbit monoclonal antibody and mouse monoclonal antibody

Comparison items Rabbit monoclonal antibody Mouse monoclonal antibody
Affinity +++++ ++
New IHC clones +++++ +++
Oldand Common IHC clones +++ ++++
Maturity for antibody drug development ++ +++++
Common IVD clones ++ ++++
Service details

Custom mouse DimAbTM development procedure&deliverables

Step Service details Deliverables Estimated production cycle (week)
Immunogen preparation Plasmid construction, mammalian cell produced immunogens or supplied by customer 7-10 weeks
Animal immunization Immunize two animals (mice) against the same antigen Crude sera and ELISA data on anti-serum titer test 8-12 weeks
Collect mouse splenocytes Dissect animal and cryopreservation; target positive B cell enrichment and single B cell expansion 100ul B cell supernatant;B cell supernatant ELISA test data 4 weeks
DimAbTM cDNA cloning, sequencing and storage IgG gene cloning, Expression vector construction; small-scale antibody production and validation; select 1-2 positive clones for full-length IgG sequencing and sequence analysis Sequencing report of one clone; ELISA data 2 weeks
DimAbTM production and validation Antibody production and identification antibody mass production and purification; antibody function identification Antibody production, purification and QC validation 4 weeks
Service Case

coming soon ...

Service Consultation
  • Submission